Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy
Year: 2015
Type: article
Study design: Clinical Trial
Source: Neuroendocrinology
DOI: 10.1159/000434723
Authors: Phillip G. Claringbold, J. Harvey Turner
Institutions: The University of Western Australia, Fremantle Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W587945571
